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 Abstract  
 
Objectives: Cocrystallization of sulfadimidine (SDM) with suitable coformers, such as 4-
aminosalicylic acid (4-ASA), combined with changes in the crystal habit can favourably 
alter its physicochemical properties. The aim of this work was to engineer SDM:4-ASA 
cocrystals with different habits in order to investigate the effect on dissolution, and the 
derived powder properties of flow and compaction.  
Methods: Cocrystals were prepared in a 1:1 molar ratio by solvent evaporation using 
ethanol (habit I) or acetone (habit II), solvent evaporation followed by grinding (habit III) 
and spray-drying (habit IV). 
Key findings: Powder X-ray diffraction showed Bragg peak position was the same in all 
the solid products. The peak intensity varied, indicating different preferred crystal 
orientation confirmed by SEM micrographs: large prismatic crystals (habit I), large plate-
like crystals (habit II), small cube-like crystals (habit III) and microspheres (habit IV). 
The habit III exhibited the fasted dissolution rate; however, it underwent a polymorphic 
transition during dissolution. Habits I and IV exhibited the highest Carr’s compressibility 
index, indicating poor flowability. However, habits II and III demonstrated improved 
flow. Spray drying resulted in cocrystals with improved compaction properties.  
Conclusions: Even for cocrystals with poor pharmaceutical characteristics, a habit can be 
engineered to alter the dissolution, flowability and compaction behavior. 
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1. Introduction 
The productivity of the pharmaceutical industry is witnessing an oncoming crisis due to 
the increasing costs for R&D, increasingly demanding regulatory requirements imposed 
by both the EMA (European Medicines Agency) and FDA (Food and Drug 
Administration) and the physicochemical properties of drug candidates in the pipeline, 
characterised by very poor aqueous solubility 1,2. Inexpensive pharmaceutical strategies 
are required to make high pharma quality affordable. Salt formation is a common 
approach to enhance drug solubility but it is not successful when the active 
pharmaceutical ingredient (API) does not contain ionisable functional groups in its 
chemical structure. Engineering of pharmaceutical cocrystals can be an advantageous 
strategy to overcome the issue of poor solubility, without the need to break or create 
covalent bonds. Hydrogen bonds are formed between the API and the coformer (one or 
more) which is usually a GRAS (generally regarded as safe) molecule with higher 
aqueous solubility3,4. In an ideal scenario, the API is transformed into a solid form that 
combines improved dissolution, that may be comparable to that obtained with the 
amorphous drug, with greater physical and chemical stability due to its crystalline 
structure5,6. However, two other factors “polymorphism” and “crystal habit” play a key 
role in the physicochemical properties of the API and then in its overall biopharmaceutical 
performance in vivo. Polymorphism is the ability of a drug to pack into different crystal 
lattice arrangements whereas, crystal habit is the external appearance of the crystal7,8.   
Common approaches to produce cocrystals in the pharmaceutical industry are grinding 
and crystallisation methods. Spray drying, a well-established scale-up technique, has also 
been shown to be a successful strategy to obtain pure cocrystals9,10. During the 
manufacturing process, a number of different variables such as solvent, degree of 
supersaturation, temperature, stirring rate, presence of other excipients, milling time and 
speed can affect both polymorphism and the growth of crystal facets and therefore the 
crystal habit11,12. At the same time, the resulting polymorphic form and crystal habit can 
affect not only the dissolution profile of the API but also the flow properties and the 
tableting-behaviour of the material13. In order to keep solid dosage form production as 
economical as possible, directly compressible powder is preferred over granulation, as 
the latter is more time and energy consuming and exposes the formulation to solvent or 
water and heat13. Even for isomorphic drugs with poor compaction behaviour and 
tendency to stick to the punches, a crystal habit could be engineered which results in a 
drug formulation with better dissolution, flowability and tableting behavior.  
SDM is a poorly-soluble anti-infective agent. In spite of the increasing antibiotic 
resistance, sulfonamides still enjoy relatively widespread use, especially in developing 
countries due to their low cost and wide antibacterial spectrum14. Sulfonamides 
commonly contain multiple hydrogen bond acceptor and donor functional groups that 
allows multiple supramolecular interactions and hence cocrystal formation15. Two 
different polymorphic forms of the cocrystal composed of one molecule of SDM and one 
molecule of 4-ASA have been reported10,16. The hypothesis underpinning this work is that 
cocrystal engineering can be used to improve the physicochemical properties of the SDM 
and also the dosage form manufacturing process, by changing the crystal habit. The 
combination of the effects of both polymorphic forms and crystal habits on 
biopharmaceutical properties, such as dissolution, and derived powder properties such as 
flowability and compaction, still remains poorly understood. For this reason, the aim of 
this work was to engineer SDM:4-ASA cocrystals with different polymorphic forms and 
crystal habits in order to investigate the effect on dissolution, wettability, flow and 
compaction properties. Comparative solid-state characterization was also performed 
using thermal analysis, powder X-ray diffraction, helium pycnometry, laser diffraction, 
specific surface area analysis and scanning electron microscopy.  
 
2. Materials and methods 
 
2.1. Materials 
SDM and 4-ASA, with a purity ≥ 99%, were purchased from Sigma–Aldrich (Wicklow, 
Ireland). Ethanol and acetone were supplied from Corcoran Chemicals (Dublin, Ireland). 
HPLC grade methanol was purchased from Fisher Scientific (Dublin, Ireland). Potassium 
hydrogen phosphate was obtained from Sigma–Aldrich (Wicklow, Ireland) and 
phosphoric acid from Merck (Darmstadt, Germany). Polyvinylpyrrolidone (PVP K90) 
was a gift from BASF (Ludwigshafen, Germany).  
 
2.2. Methods 
 
2.2.1. Preparation of polymorphic forms and habits of SDM:4-ASA cocrystal 
All cocrystals were prepared using a 1:1 molar ratio (SDM:4-ASA). 
Cocrystal Polymorph I: liquid-assisted milling 
Liquid-assisted co-milling was carried out in a Retsch PM100 planetary ball mill (Haan, 
Germany) using three stainless steel balls (Ø=20 mm) in each milling jar (50 ml). Five 
drops of ethanol were added to the solid mix (1289.2 mg of SDM and 710.67 mg of 4-
ASA) using a 3.5 ml disposable transfer pipette (Fisher Scientific, Dublin, Ireland) prior 
to milling. The rotation speed of the solar disk was set to 400 rpm. Total milling time was 
35 min. A pause period of 5 min was made after 15 min of milling in order to avoid high 
temperature in the jar and thus the risk of melting/decomposition of the compounds10.  
Cocrystal Polymorph II- Habit I: Crystallization from ethanol 
Polymorph II-Habit I was prepared as previously described by Grossjohann et al.10 with 
a few modifications. 4-ASA (153.4 mg) was dissolved in ethanol (40 ml) in a round 
bottom flask. Afterwards, SDM (278.3 mg) was added to the solution and another 10 ml 
of ethanol were incorporated. Water bath sonication (10 s) followed by microwaving (10 
s) were required to ensure complete dissolution. Ethanol was evaporated using a rotavapor 
(Buchi, Flawil, Switzerland) at 250 mbar pressure and 55 °C. Immediately after solvent 
evaporation, the flask was removed in order to avoid a colour change from white to 
brownish. The flask was kept in the oven at 50 °C for 5 min to remove any residual solvent 
left and then the powder was recovered.  
Cocrystal Polymorph II- Habit II: Crystallization from acetone 
4-ASA (153.4 mg) was dissolved in acetone (40 ml) in a round bottom flask. Afterwards, 
SDM (278.3 mg) was added to the solution and another 10 ml of acetone was 
incorporated. The rest of the process was identical to that described above. 
Cocrystal Polymorph II- Habit III: Crystallization from ethanol followed by dry 
milling 
Powder obtained after solvent evaporation using ethanol was milled in a Retsch PM100 
planetary ball mill (Haan, Germany) using three stainless steel balls (Ø=20 mm) in a 50 
ml milling jar. A sample mass of 2 g of Polymorph II-Habit I was used. The rotation speed 
of the solar disk was set to 400 rpm and the total milling time was 10 min. 
Cocrystal Polymorph II- Habit IV: Spray-drying 
Spray drying was performed using a Buchi B-290 Mini Spray Dryer (Buchi, Flawil, 
Switzerland) operating in the open-mode. Solution concentrations of 1% (w/v) of SDM:4-
ASA (1:1 molar ratio, 644.6 and 355.3 mg respectively) were prepared using ethanol (100 
ml). The solutions were delivered to a 2-fluid nozzle (0.7 mm nozzle tip and a 1.5 mm 
diameter nozzle screw cap) using a peristaltic pump at a speed of 30% (9–10 ml/min). 
Nitrogen (at 6 bar) was used as the drying gas in a co-current mode with aspirator capacity 
set to maximum (100%). The flowmeter for the standard 2-fluid nozzle was set at 4 cm 
which is equivalent to 473 NL/h. The inlet temperature was fixed at 78°C and the outlet 
temperature varied between 50°C and 57°C10. 
 
Physical mixture 
4ASA (153.4 mg) and SDM (278.3 mg) raw materials were manually mixed using a 
mortar and pestle in a molar ratio 1:1.  
2.2.2. Physicochemical characterisation 
Powder X-ray diffraction (PRXD) 
Powder X-ray analysis was performed using a Miniflex II Rigaku diffractometer with Ni-
filtered Cu Kα radiation (1.54 Å). The tube voltage and tube current used were 30 kV and 
25 mA, respectively. The PXRD patterns were recorded (n=3) from 5° to 40° on the 2 
theta at a step scan rate of 0.05° per second17. Rigaku Peak Integral software was used in 
the determination of peak intensity for each sample using the Sonnefelt-Visser 
background edit procedure. 
Differential scanning calorimetry (DSC) 
Differential scanning calorimetry was performed using a Mettler Toledo DSC 821e 
instrument under nitrogen purge. Sample powders (4-6 mg) were placed in aluminium 
pans (40 µl), sealed, pierced to provide three vent holes and heated at a rate of 10 °C/min 
in the temperature range of 25 to 220 °C. Calibration of the instrument was carried out 
using indium as standard. The DSC system was controlled by Mettler Toledo STARe 
software (version 6.10) working on a Windows NT operating system. Temperatures of 
melting events (n=3) refer to onset temperatures10.  
Particle size distribution analysis (PSD) 
The geometric particle size distributions (PSD) were determined by laser diffraction using 
a Malvern Mastersizer 2000 (Malvern Instruments Ltd., Worcestershire, U.K.). Particles 
were dispersed using a Scirocco dry feeder instrument with 1 bar pressure. An obscuration 
of 1−6% was obtained under a vibration feed rate of 50%. Liquid measurements in 
deionised water were also carried out using a Hydro 2000 µP accessory (for small volume 
wet sample dispersions) at 2000 rpm. Data were analysed based on the D10, D50, D90 
and the span of the PSD. Results reported are the average of three analyses.  
 
Surface area measurements  
To determine the specific surface area (TBET) by the Brunauer, Emmett, Teller (BET) 
isotherm method, a Micromeritics Gemini VI 2385C (Micromeritics, Norcross, GA, 
USA) surface area analyser was used. The amount of nitrogen adsorbed at 6 relative 
pressure points in the relative pressure (P/Po) range of 0.05 to 0.3, with an equilibration 
time of 10 s, was used for the BET analysis. Each average result is calculated on the basis 
of three measurements. Free space was determined separately for each sample using 
helium gas. Saturation pressure Po was determined prior to the measurement of each 
sample18. Samples were prepared by purging under N2 overnight at 25 °C. 
 
Density measurements 
The true density was measured by an Accupyc 1330 Pycnometer (Micromeritics, 
Norcross, GA, USA) using helium (99.995% purity) to determine the volume of the sample. 
Samples were dried under N2 atmosphere prior to measurement for 24 h at 25 °C
18. A 5 
cm3 graduated cylinder was used in the bulk density (aerated density) determination of 
samples. The container was filled with accurately weighed sample and the top was 
levelled. The density was calculated as the ratio of the mass to the volume of the sample. 
The tap density was determined similarly to the aerated density, but the volume taken for 
calculations was that after 300 strokes. Each average result is calculated on the basis of 
three measurements. Carr’s compressibility index was calculated using the bulk and tap 
density values according to the following equation19: 
 
Carr’s compressibility index = (tap density − bulked density)/ tap density ×100  (Eq. 1) 
 
Scanning electron microscopy (SEM)  
Surface images of powders were performed at various magnifications by SEM using a 
Zeiss Supra Variable Pressure Field Emission Scanning Electron Microscope (Germany) 
equipped with a secondary electron detector at 5 kV. Samples were glued onto aluminium 
stubs and sputter-coated with gold under vacuum prior to analysis. 
 
Wettability studies 
Compacts were prepared by compressing powder (300 mg) using a Perkin Elmer 
hydraulic press. A 13 mm punch and die set at a pressure of 8 tonnes for 1.5 min was 
used. Compacts were placed on a stage and raised to an appropriate level. Contact angles 
made by deionised water with the compacts were measured using the sessile drop method 
on a drop shape analyser (FTA 125, First Ten Angstrom, Virginia, USA) From a captured 
video, the contact angle was calculated based on the Young-Laplace equation20. The slope 
of the tangent to the drop at the liquid−solid−vapor interface line was calculated. All 
measurements were performed in triplicate under ambient conditions of 25 ± 2 °C7.  
2.2.3. Compaction studies at a single compression force  
Biconvex tablets (n=10, 200 mg) were compressed using a Natoli NP-RD10 (Saint 
Charles, USA) laboratory scale single punch tablet press supplied with an Enerpac (USA) 
AC RC53 piston working in the range from 0 to 10 tons and standard concave 10 mm 
diameter punch and die tooling. Pressure was released immediately after the desired 
compression pressure was reached. Tablets were pushed out of the die using the bottom 
punch. To lubricate the tablet press tooling, the die and upper punch were dusted, using a 
paint brush, with magnesium stearate. A set of ten tablets was subjected to radial hardness 
testing using a Dr. Schleuniger, Pharmatron, model 6D tablet tester. Compaction 
properties were quantified in terms of hardness achieved at the applied compaction 
pressure of 6 KN. Also, it was monitored whether or not the tablet capped under the 
applied pressure and if the breakage of the tablet occurred in a consistent manner18. 
 
2.2.4. Flow-through cell dissolution studies 
A single flow-through cell dissolution apparatus (Sotax) in an open-loop configuration 
with an internal diameter of 12 mm was used. One ruby bead of about 5 mm was 
positioned at the apex of the bottom cone to equalize the jet of fluid entering the cell. 
Powder was loaded into the flow-through cell as illustrated in Figure 1.  
The powder to be examined was sieved through a 300 µm sieve before performing the 
dissolution study. The amount of powder loaded in every study was 300 mg. A cellulose 
Whatman® filter grade 1 (11 µm), a glass microfiber filter (Whatman® GF/D, 2.7 μm), a 
glass microfiber Whatman® filter grade GF/F (0.7 µm) and a hydrophilic membrane Pall 
Supor® (0.45 µm) were positioned sequentially at the inner top of the cell to retain 
undissolved material. The dissolution medium was pumped (120 pulses per minute) 
through the cell at a flow rate of 8 ml/min over 180 min. Studies were performed using 
two different media: i) deionised water (pH 5.5) and ii) deionised water (pH 5.5) with 
0.1% PVP K90. The temperature was maintained at 37 ± 0.5 °C during testing. Samples 
were collected from the flow-through cell at different time points (every 5 min from 0 to 
30 min, every 10 min from 30 to 60 min and every 15 min from 60 to 180 min) and then 
were diluted with mobile phase and analysed by HLPC (method described below) to 
calculate the percentage of drug dissolved at each time point. 
Flow-through cell PXRD studies  
Samples were collected from the inside of the cell at different time points, dried at 
ambient temperature under a nitrogen atmosphere and analysed by PRXD.  
 
2.2.5. Quantification by HPLC 
The concentration of SDM and 4-ASA was determined using an Alliance HPLC with a 
Waters 2695 Separations module system and Waters 2996 Photodiode array detector. The 
mobile phase consisted of methanol/buffer pH 6.5 40/60 (v/v). The buffer was prepared 
from a 50 mM dipotassium phosphate solution adjusted to pH 6.5 with phosphoric acid. 
The mobile phase was vacuum filtered through a 0.45 μm membrane filter (Pall Supor® 
0.45 µm, 47 mm) and bath sonicated for 5 min. Separation was performed on a 
Phenomenex Inertsil ODS (3) C18 column (150 mm length, diameter 4.6 mm, particle 
size 5 μm) at a UV detection wavelength of 265 nm with an injection volume of 20 μL. 
The elution was carried out isocratically at ambient temperature with a flow rate of 1 
ml/min. The total run time per sample was 6 min. Elution times for 4ASA and SD were 
1.9 min and 4.0 min respectively. For peak evaluation Empower software was used. The 
calibration curves were linear for both components between 100 μg/ml – 0.05 μg/ml (R2 
> 0.9999). The linear regression calibration curve obtained for 4ASA was y= 91157x 
+8454.8 and for SD was y= 80548x + 3498.7. 
 
2.2.6. Mechanistic mathematical models 
In order to investigate the release from the different cocrystal habits, the dissolution data 
obtained was fitted using the following kinetic equations21,22: first order (Eq. 2), Hixson–
Crowell (Eq. 3) and Korsmeyer–Peppas (Eq. 4): 
 
ln 𝑄𝑡 = ln 𝑄0 + 𝐾1𝑡                                         (Eq.2) 
 
𝑄∞
1/3
− (𝑄∞−𝑄𝑡)
1/3 =  𝐾𝑠𝑡                            (Eq. 3) 
𝑄𝑡
𝑄∞
= 𝐾𝐾𝑃𝑡
𝑛                                                     (Eq. 4) 
Where Qt is the amount of drug dissolved in time t, Q0 is the initial amount of drug in the 
solution (most times, Q0=0), 𝑄∞  is the initial amount of drug in the tablet; 
𝑄𝑡
𝑄∞
 is the 
fraction of drug release at time t; K1 is the first order release constant, Ks is a constant 
incorporating the surface-volume relation; KKP is a constant that describes the structural 
and geometric characteristics of the drug dosage form; n is the release exponent which 
describes the drug release mechanism. The n can have a value of 0.5, 0.45 or 0.43 when 
the particle shape is a thin film, a cylinder or a sphere respectively which corresponds to 
Fickian release controlled by diffusion. Anomalous non-Fickian transport is described 
when n is between those values and 1 (0.5 < n < 1 for thin films, 0.45 < n< 1 for cylinder 
and 0.43 < n < 1 for spheres). n=1 corresponds with zero order release23. To test the 
applicability of the drug release model, the regression coefficient (R2) was used21,24.   
 
2.2.7. Molecular modelling 
The program Mercury (version 3.5.1., Cambridge Crystallographic Data Centre, 
Cambridge, UK) was used for calculation of X-ray powder patterns on the basis of the 
single crystal structure.  Miller’s indices of various facets of the crystal were identified 
using Mercury and it was also used to visualise the molecular arrangement on different 
crystal facets of the cocrystal.  
 
2.2.8. Statistical analysis 
Statistical analysis was performed via one-way ANOVA Test using Minitab 16 (Minitab 
Ltd, Coventry, UK) followed by Tukey’s test considering p-values for statistical 
significance < 0.05. Linear regression analysis was performed using the method of least 
squares by Microsoft® Excel software. The adequacy of the fit was assessed from the 
regression coefficient (R2).  
 
3. Results and discussion 
 
3.1. Preparation and characterisation of SDM:4-ASA polymorphic cocrystals and 
crystal habits 
Polymorph I was successfully produced by liquid-assisted milling while polymorph II 
was obtained after crystallisation from different solvents (ethanol or acetone) or spray-
drying. The yield was higher than 75% in all the manufacturing processes apart from 
spray drying, which resulted in 45% yield. 
Results of thermal analysis are shown in Figure 2A and Table 1. DSC results showed that 
the melting point of the polymorphm I and II was between those of SDM (Tm = 197.1 ± 
0.1) and 4-ASA (Tm = 145.6 ± 0.4). The 1:1 molar ratio was employed in the preparation 
of the different polymorphic forms and crystal habits because a single melting event was 
obtained unlike the non-equimolar mixtures as previously described by Grossjohann et 
al.10. The equimolar physical mixture also exhibited a single melting point that was 
between the single components but it was shifted to lower temperatures (Tm = 159.8 ± 
0.7). The melting point of the five cocrystals was between 166 and 171 ⁰C. 
PXRD analysis showed that all the diffraction peaks of the equimolar physical mixture of 
SDM and 4-ASA could be superimposed with those of the two individual components 
(Figure 2B). However, the diffractograms of both polymorphic cocrystals of SDM and 4-
ASA showed patterns with characteristic diffraction peaks which differ between one 
another and also differ from those of the single components. Bragg peak positions of 
polymorph II was the same in all the crystal habits (I to IV). However, the peak intensity 
varied, indicating different preferred orientation of the crystallographic planes (Fig 2B). 
The peak area, relating to the degree of crystallinity of the polymorph I and polymorph II 
(habit I to IV) was 6189, 4541, 4977, 4306 and 3871 expressed as intensity (arb. units)/2 
θ degrees respectively which showed a reduction in the degree of crystallinity after spray 
drying (habit IV) and solvent evaporation followed by milling (habit III). A graphical 
presentation of XRPD peak intensities of prominent planes in Polymorph II- Habits I –
IV is shown in Figure 3. The intensity of (1,2,1) and (3,0,1) facets was increased after 
spray drying whereas after milling, the facet (1,1,0) was also prominent. Polymorph II-
Habit II showed characteristic prominent (5,0,1) and (1,2,1) facets whereas habit I 
exhibited (2,0,2) and (3,0,1) facets of higher intensity. Polymorph I exhibited prominent 
(0, 1, -1) and (2, 0, -2) facets. 
SEM micrographs clearly showed the difference in the crystal habits: small prismatic 
crystals (Polymorph I), large prismatic crystals (Polymorph II-habit I), large plate-like 
crystals (Polymorph II-habit II), small cube like-crystals (Polymorph II-habit III) and 
microspheres (Polymorph II-habit IV) (Figure 4). The crystal habit of the physical 
mixture was a mixture of the crystal habits of the single components.  
Particle size distribution analysis showed that the spray dried sample (polymorph II-Habit 
IV) had the smallest median particle size (D50) 5.7 ± 0.7 µm which corresponds with the 
highest surface area (3.669 ± 0.011 m2/g) (Table 1), whereas the polymorph II- habit II 
exhibited the largest D50 (60.5 ± 6.2 µm) and the lowest surface area (0.758 ± 0.065 m
2/g). 
The median particle size of the polymorph II- habit I was 2-3 fold lower than polymorph 
II-habit III and polymorph I. However, both polymorph II-habit III and polymorph I 
exhibited higher surface areas than polymorph II-habit I (1.694 and 2.830 m2/g versus 
1.136 m2/g), which could be due to the fact that the bigger aggregates consisted of crystals 
of smaller size, as can be observed in the SEM micrographs (Fig. 4). 
3.2. Carr’s Compressibility Index  and compaction properties  
Tabletability can be defined as the capacity of a powdered material to be transformed into 
a tablet of specified strength under the effect of compaction pressure25.  Ideally, the target 
for pharma companies would be to engineer a crystal habit that is suitable for direct 
compression with only a low amount of excipients, which forms a stable compact at low 
punch forces, has good flowability and a low tendency to stick to punches. 
 
Differences in Carr’s compressibility Index (as an indicator of flow) and compaction 
properties between the polymorphs and habits are shown in Table 1. The differences in 
bulk density may be related to differences in crystal habits which lead to different contact 
points and frictional and cohesive forces between crystals. In general, the lower Carr´s 
compressibility index, the better the flow26. All the cocrystals examined demonstrated 
relatively poor flow, with Carr’s Compressibility Indices greater than 30% in all cases. 
For this reason, further powder rheometry studies were not performed. Polymorph II- 
habit I exhibited the highest Carr’s index (43.9 ± 3.1%) indicative of poorest flowability, 
similar to the physical mixture of the single components, which could be due to its crystal 
habit, which is characterised by large prismatic crystals with pointed edges. Polymorph 
II- habit IV also showed very poor flow (38.9 ± 4.5%), probably due to the small particle 
size and also the manufacturing process (spray drying) that frequently leads to 
electrostatic charged powders.  
 
A decrease in particle size enhanced the compact hardness, due to smaller crystals having 
a larger number of contact points between crystals in the compacts27. Similar observations 
have been previously reported in sulfamerazine polymorphs by other authors28. Spray 
dried (polymorph II- habit IV) and milled materials (polymorph I and polymorph II – 
habit III) resulted in compacts with increased hardness and less tendency to cap. 
Cocrystals obtained by solvent evaporation (polymorph II- habits I & II) exhibited 
significantly poorer compaction properties indicating weak bonding between particles 
and difficulty to orient in different directions and fracture during tableting, which could 
be related to their crystal shape (large prismatic and plate-like crystals). 
3.3. Dissolution studies and wettability 
The equimolar physical mixture exhibited the fastest dissolution rate at earlier time points 
(0-10 min) when the release of both 4-ASA and SDM was taken into account (Fig. 5a). 
However, it can be observed in Fig. 5b that the dissolution was incongruent, resulting in 
much larger and faster release of 4-ASA compared to SDM. The fast dissolution of the 
physical mixture is in good agreement with the wettability results in Table 1 and as shown 
by other authors, the wettability of a powder can be reliably estimated by the contact angle 
measured on compressed powder29. The lower contact angle of the physical mixture can 
be related to its higher surface hydrophilicity. 4-ASA is a more hydrophilic compound 
(water solubility= 2 g/L at 20 ⁰C30) than SDM (water solubility= 1.5 g/L at 29 ⁰C31) but 
also than the cocrystals, leading to a good wettability that affects the dissolution at initial 
times. However, wettability is not a good tool to assess the overall dissolution profile at 
longer periods of time. The amount of SDM dissolved from the physical mixture at 60 
min in water at 37 °C was 2.5-fold lower compared to polymorph I and polymorph II-
habit III. 
The overall amount dissolved at 60 min was higher for polymorph I & polymorph II-habit 
III followed by polymorph II-habit I> polymorph II-habit II> physical mixture > 
polymorph II-habit IV (Fig 5a). Surprisingly, polymorph II-habit IV displayed the lowest 
dissolution rate in spite of having the smallest particle size and highest surface area. To 
investigate this fact, the particle size analyses of the samples suspended in deionised water 
as medium were performed, showing a dramatic particle aggregation for the polymorph 
II-habit IV (D50= 1042.3 ± 11.6 µm) and also but to a lesser extent for the polymorph II-
habit II (D50= 172.5 ± 5.0 µm). Another factor that explains the different dissolution 
profile among cocrystals is the polymorphic transitions that can occur in situ during 
dissolution. Polymorph II- habit III was transformed rapidly (after 1 min) into polymorph 
I during dissolution, as was confirmed by PXRD due to the presence of a prominent peak 
at 10.25 2θ degrees (Fig. 6a). Its small particle size (and therefore high solid-solvent 
interfacial contact area) and its manufacturing process, which was similar to that of the 
polymorph I, could explain why the polymorphic transition occurred, resulting in an 
almost identical dissolution profile. Polymorph II-habit IV was partially transformed into 
polymorph I, which could also be related to the small particle size and higher surface area 
that facilitates the polymorphic transformation. However, an extra peak at 9.35 2θ degrees 
corresponding to SMD was also observed, which could explain why the dissolution rate 
was slowed down. Polymorph II-habit I was stable during the entire dissolution test 
whereas polymorph II-habit II showed the presence of both peaks at 10.25 and 9.35 2θ 
degrees at early time points (1 min) which were not detected at longer times, but this may 
explain why the dissolution rate for polymorph II- habit II was slower than polymorph II-
habit I (Fig. 5a).  
Both polymorph I and polymorph II-habit III cocrystals exhibited congruent dissolution, 
characterised by an equimolar release for SDM and 4-ASA over time (Fig. 5b). However, 
the dissolution was incongruent, not only for the physical  mixture, but also for the other 
three cocrystals due to the faster release of 4-ASA (for polymorph II- habit I & II) or the 
faster release of SDM (for polymorph II-habit IV). 
Using low polymer concentrations like PVP has been used as a successful strategy to 
minimise particle aggregation and inhibit precipitation from a supersaturated solution32-
34. For this reason, further dissolution experiments were performed by adding 0.1% w/w 
PVP to the dissolution medium (Fig. 5c). The dissolution rate of polymorph II-habit IV 
was significantly enhanced at early time points (0-20 min) resulting in a 3.3-fold higher 
amount of SDM dissolved at 60 min. This can be explained by the fact that particle 
agglomeration was inhibited by the presence of PVP. The dissolution rate of polymorph 
II-habit I was also slightly increased in PVP although the same percentage of cocrystal 
was dissolved in both media at 60 min. Nevertheless, in the case of polymorph II-habit II 
there was a dramatic 13-fold reduction in the amount of SDM dissolved after 60 min 
when PVP was used. This could be due to the preparation process, which involves acetone 
as solvent. Further investigation is required to identify if traces of acetone in the cocrystal 
could lead to PVP precipitation in the surroundings of the particles at earlier time points, 
or if some other phenomenon explains the hindered release.  
The addition of PVP prevented incongruent dissolution and maintained the release of both 
cocrystal components resulting in an equimolar dissolution (Fig. 5d). Free SDM was not 
detected during the dissolution process in any of the cocrystals, as confirmed by PXRD 
(Fig 6b). Nevertheless, polymorph II-habit III was also transformed into polymorph I in 
the presence of PVP. It appears that, not only does the smaller particle size, that presents 
a larger surface area to the dissolution medium, trigger the polymorphic transition, but 
also the manufacturing process is crucial in determining the stability of the polymorph II. 
Hence, depending on process conditions a manufacturing process could produce different 
habits which could lead to different polymorphic transitions. 
3.4. Mathematical modelling 
The results of the curve fitting to the different mathematical models for dissolution in 
both deionised water and water/PVP 0.1 % (w/v) are shown in Table 2. From comparison 
of the regression coefficients, it was found that the Hixson-Crowell model provided a 
good fit for all the cocrystals, except for physical mixture where the Korsmeyer-Peppas 
model provided a better fit.  
The Hixson-Crowell model, also called the cube root law, applies to pharmaceutical 
dosage forms, where the dissolution takes place in planes that are parallel to the drug 
surface if the particle dimensions diminishes proportional in a way that the initial 
geometrical form keep constant all the time21. The application of the release profiles to 
Hixson-Crowell model indicates that a change in surface area and diameter of the particles 
occur with progressive dissolution as a function of time35. The major disadvantages of 
this model are: i) sink conditions are required, ii) the geometry of the dissolving particles 
is considered spherical and without any change over time and iii) the particles remain 
intact and do not disintegrate into smaller fragments during dissolution22. The first 
assumption is usually correct during the flow-through cell dissolution studies as an open-
loop system was used, however, the other two assumptions may not be valid, which can 
lead to deviations from the models. This was the case for the physical mixture, probably 
because the geometrical shape of the particles is far from spherical. In this case, the 
Korsmeyer-Peppas model provided a better fit where the release exponent (n) was 0.29. 
A value of n ≤ 0.43 indicates a time dependence of drug release by Fickian diffusion from 
a thin film. The physical mixture is a two component system where one of the components 
(4-ASA) is more soluble than the other one (SDM). During the dissolution experiment, 
the formation of a very large aggregate, similar to a matrix system, was observed over 
time. Therefore, SDM release was hindered as SDM molecules have to diffuse from this 
system in order to be dissolved, which could explain this type of release.   
3.5.  Molecular modelling 
The visualisation of the cocrystal packing along the axis a and c is represented in Figure 
7. The main functional groups that can contribute to the surface chemistry are –NH2, -OH 
and –COOH in the 4-ASA and the –SO2 and -NH2 in the SDM. Face indexation data 
revealed that the relative abundance of major facets on the surface chemistry differed 
significantly among the four crystal habits of polymorph II (Fig. 3). The percent 
contribution of (1,1,0) facet on the surface of the polymorph II-habit III was higher 
compared to the other habits. The presence of hydrophilic groups (such as -SO2) at this 
facet could explain the faster dissolution kinetics (Fig 7b). Similarly, the (0,1,-1) facet 
corresponding to the prominent peak at 10.25 2θ degrees in the polymorph I is 
characterised by the presence of –SO2 (Fig. 7c). In addition, both polymorph I and 
polymorph II-habit III had the same contact angle, which is indicative of similar 
functional groups at the surface chemistry leading to similar dissolution profiles both in 
water and water/PVP. 
 
4. Conclusions 
A specific crystal habit can be the result of multiple factors during the manufacturing 
process. However, the crystal habit can have a great influence on the physicochemical 
properties of the drug. Even for cocrystals with poor pharmaceutical characteristics, a 
habit can be engineered that results in better flowability, tableting and dissolution 
behaviour. Milling and spray drying resulted in powders with enhanced hardness due to 
the smaller particle size but only milled materials led also to acceptable flow, as spray 
dried powders were electrostatically charged hindering the flowability. The dissolution 
properties were also affected by the cocrystal habit resulting in a higher overall 
dissolution rate in deionised water for milled powders followed by powders obtained by 
crystallization from solution and then by spray drying. In spite of the spray dried powder 
exhibiting better micromeritic characteristics for dissolution (smaller particle size and 
higher surface area), it suffered from agglomeration, which notably reduced its 
dissolution rate in water, relative to other crystal habits examined. However, the presence 
of 0.1% w/v of PVP in the medium had a large impact on inhibiting particle 
agglomeration and then enhancing the dissolution of the spray dried cocrystal. 
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Figure captions 
Figure 1. Schematic diagrams showing the position of the powder in the flow-through 
cell. 
Figure 2. DSC thermograms and PXRD patterns of SDM: 4-ASA (1:1 molar ratio) 
cocrystal and unprocessed materials. A) DSC thermograms; B) PXRD patterns. Key: a) 
Unprocessed SDM; b) Unprocessed 4-ASA; c) Physical mixture; d) Polymorph I; e) 
Polymorph II-Habit I; f) Polymorph II-Habit II; g) Polymorph II- Habit III and h) 
Polymorph II-Habit IV. 
Figure 3. Graphical presentation of PXRD peak intensities of prominent planes in 
Polymorph II- Habits I -IV. Key: -♦- Polymorph II-Habit I; -■-Polymorph II-Habit II; 
-▲- Polymorph II- Habit III and -x- Polymorph II-Habit IV. 
Figure 4. SEM micrographs of unprocessed API (sulfadimidine) and coformer (4-
ASA) and cocrystals. 
Figure 5. Dissolution profiles and stoichiometry of dissolution of different 
polymorphs and crystal habits at 37°C.  
A) Dissolution profiles in deionised water. Key: Physical mixture (- -●- -); Polymorph 
I (- -♦- -); Polymorph II- Habit I (―■―); Polymorph II- Habit II(―▲―); Polymorph 
II- Habit III(―♦―) and Polymorph II- Habit IV (―●―) .  
B) Stoichiometry during dissolution in deionised water. Key: Closed symbols refer to 
SDM release and open symbols refer to 4-ASA release.  Physical mixture [SDM (- -●- -
), 4-ASA(- -○- -)]; Polymorph I [SDM (- -♦- -), 4-ASA (- -◊- -)]; Polymorph II- Habit I 
[SDM (―■―),4-ASA (―□―)]; Polymorph II- Habit II [SDM (―▲―), 4-ASA 
(―Δ―)]; Polymorph II- Habit III [SDM (―♦―), 4-ASA  (―◊―)], and Polymorph II- 
Habit IV [SDM (―●―), 4-ASA (―○―)].  
C) Comparison of dissolution profile in deionised water and water/PVP 0.1%. Key: 
Polymorph I, in water (- -♦- -), in water/PVP (- -◊- -); Polymorph II- Habit I, in water 
(―■―),in water/PVP (―□―); Polymorph II- Habit II, in water (―▲―), in water/PVP 
(―Δ―); Polymorph II- Habit III in water (―♦―), in water/PVP  (―◊―), and 
Polymorph II- Habit IV, in water (―●―), in water/PVP (―○―).  
D) Stoichiometry during dissolution in deionised water/ PVP 0.1%. Key: Closed 
symbols refer to SDM release and open symbols refer to 4-ASA release.  Polymorph I 
[SDM (- -♦- -), 4-ASA (- -◊- -)]; Polymorph II- Habit I [SDM (―■―),4-ASA (―□―)]; 
Polymorph II- Habit II [SDM (―▲―), 4-ASA (―Δ―)]; Polymorph II- Habit III [SDM 
(―♦―), 4-ASA  (―◊―)], and Polymorph II- Habit IV [SDM (―●―), 4-ASA (―○―)]. 
Figure 6. Comparison of PXRD patterns before and after dissolution. A) In water at 
37°C. B) In water/PVP 0.1% at 37°C. 
Figure 7. Visualization of crystal structure and molecular surface packing. Key: A) 
Crystal structure of SDM:4-ASA 1:1 polymorph II cocrystal viewed along the c axis; B) 
visualization of molecular surface packing of polymorph II along with surface chemistry 
of (110) facet using Mercury 3.5.1. software and C) visualization of molecular surface 
packing of polymorph I along with surface chemistry of (0,1,-1) facet using Mercury 
3.5.1. software.
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Table 1. Micrometric properties and physicochemical characteristics of 4ASA:SD (1:1 molar ratio) cocrystals form I, form II, physical mixture 
and raw materials. Key: Melting onset temperatures (Tm), heating fusion (AHf), Span calculated as (D90 – D10)/D50, capping expressed as: +++ 
when more than 5 out of 10 tablets capped under the applied pressure; ++ when 3 or 4 out of 10 tablets capped under the applied pressure; + when 
1 or 2 out of 10 tablets capped under the applied pressure and – when 0 out of 10 tablets capped under the applied pressure. 
Sample 
Preparation 
(Yield in %) 
Tm 
(°C) 
AHf 
(J/g) 
BET 
surface 
area 
(m2/g) 
Contac
t angle 
(°) 
Hardness 
(N) / 
(Capping) 
True 
Density 
(g/cm3) 
Bulk 
density 
(g/cm3) 
Tapped 
density 
(g/cm3) 
Carr’s 
index 
(%) 
D10 (µm) D50 (µm) D90 (µm) Span 
4-ASA Raw material 
145.6 ± 
0.4 
338.9 ± 
2.1 
- - - - - - - - - - - 
SDM Raw material 
197.1 ± 
0.1 
128.7 ± 
0.6 
- - - - - - - - - - - 
Physical 
mixture 
Mortar and 
pestle 
159.8 ± 
0.7 
188.9 ± 
0.4 
0.875  
± 0.025 
31.1 ± 
2.7 
48.9 ± 2.3 
(++) 
1.49 ± 
1.5 x 10-3 
0.313 ± 
1.1 x 10-2 
0.547 ± 
3 x 10-3 
42.8 ± 
2.3 
3.7 ± 
0.05 
9.4  ± 
0.5 
32.6  ± 
0.2 
3.1 
Polymorph I 
Liquid-assisted 
milling 
(87.2 ± 3.7) 
171.1 ± 
1.9 
228.6 ± 
1.1 
2.830  
± 0.003 
61.9 ± 
2.6 
43.3 ± 5.7 
(+) 
1.45 ± 
7 x 10-4 
0.373 ± 
1.3 x 10-2 
0.578 ± 
7 x 10-3 
35.4 ± 
2.9 
5.1  ± 
0.01 
44.9  ± 
0.02 
266.1  ± 
12.1 
5.8 
Polymorph II 
– Habit I 
Solvent 
evaporation 
using EtOH 
(90.6 ± 4.5) 
167.6 ± 
0.8 
209.4 ± 
2.6 
1.136  
± 0.012 
46.7 ± 
2.4 
28.1 ± 2.9 
(+++) 
1.41 ± 
1.4 x 10-4 
0.216 ± 
9 x 10-3 
0.385 ± 
6 x 10-3 
43.9 ± 
3.1 
3.4  ± 
0.03 
15.6  ± 
0.02 
87.7  ± 
0.01 
5.4 
Polymorph II 
– Habit II 
Solvent 
evaporation 
using Acetone 
(81.4 ± 5.6) 
167.9 ± 
0.8 
188.5 ± 
2.1 
0.758 ± 
0.065 
73.2 ± 
0.1 
20.5 ± 5.3 
(+++) 
1.37 ± 
2.1 x 10-3 
0.384 ± 
0.021 
0.554 ± 
0.002 
30.7 ± 
2.8 
4.9 ± 0.7 
60.5 ± 
6.2 
 
273.8 ± 
15.2 
4.5 
Polymorph II 
– Habit III 
Solvent 
evaporation 
using EtOH 
followed by 
milling 
(78.6 ± 3.5) 
170.2 ± 
0.6 
212.5 ± 
2.3 
1.694 ± 
0.084 
 
63.4 ± 
2.1 
53.6 ± 4.4 
(-) 
1.41 ± 
1.1 x 10-3 
 
0.238 ± 
0.019 
0.346 ± 
0.19 
31.2 ± 
3.3 
2.9 ± 0.3 
24.8 ± 
2.5 
180.4 ± 
15.9 
7.2 
Polymorph II 
– Habit IV 
Spray-drying 
(45.2 ± 3.3) 
168.5 ± 
0.7 
206.3 ± 
3.1 
3.669 ± 
0.011 
65.3 ± 
1.75 
51.2 ± 2.9 
(-) 
1.41 ± 
1.9 x 10-3 
0.296 ± 
0.015 
0.484 ± 
0.021 
38.9 ± 
4.5 
1.6 ± 0.1 5.7 ± 0.7 
124.3 ± 
19.4 
21.5 
Table 2. Regression coefficient (R2) values in the analysis of the dissolution data (from 0 to 30 min) for polymorph I, II and physical mixture in 
water and water/PVP 0.1% at 37 °C using the following kinetic equations: first order, Hixson–Crowell and Korsmeyer–Peppas. Key: n is the release 
exponent which describes the drug release mechanism. 
Cocrystal Medium First Order 
Hixson–
Crowell 
Korsmeyer–
Peppas (n) 
Polymorph I 
Water 0.933 0.999 0.996 (0.69) 
Water/PVP 0.917 0.976 0.999 (0.50) 
Polymorph 
II- Habit I 
Water 0.943 0.999 0.991 (0.62) 
Water/PVP 0.911 0.996 0.999 (0.61) 
Polymorph 
II- Habit II 
Water 0.929 0.986 0.997 (0.50) 
Water/PVP 0.934 0.989 0.993 (0.88) 
Polymorph 
II- Habit III 
Water 0.920 0.999 0.997 (0.74) 
Water/PVP 0.915 0.996 0.999 (0.65) 
Polymorph 
II- Habit IV 
Water 0.914 0.989 0.986 (0.53) 
Water/PVP 0.869 0.939 0.999 (0.38) 
Physical 
mixture 
Water 0.879 0.866 0.994 (0.29) 
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